• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

DEVELOPMENT OF CXCR4 ANTAGONISTS TARGETED TO ANTI-CANCER-METASTATIC AGENTS AND ANTI-HIV AGENTS

Research Project

Project/Area Number 15590099
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Drug development chemistry
Research InstitutionKYOTO UNIVERSITY

Principal Investigator

TAMAMURA Hirokazu  Kyoto University, Graduate School of Pharmaceutical Sciences, Associate Professor, 薬学研究科, 助教授 (80217182)

Project Period (FY) 2003 – 2004
Project Status Completed (Fiscal Year 2004)
Budget Amount *help
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2004: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2003: ¥1,800,000 (Direct Cost: ¥1,800,000)
Keywordschemokine receptor / CXCR4 antagonist / HIV infection / cancer metastasis / leukemia / rheumatoid arthritis / T140 / cyclic peptide / 癌転移抑制剤 / 低分子化 / 膵臓癌 / 乳癌
Research Abstract

The chemokine receptor, CXCR4, is a GPCR that transduces signals of its endogenous ligand, CXCL12 (stromal cell-derived factor-1, SDF-1). The CXCL12-CXCR4 system has recently been proven to be involved in several problematic diseases, including HIV infection, cancer cell metastasis, leukemia cell progression and rheumatoid arthritis (RA) : First, CXCR4 was identified as a second receptor that is utilized in T cell line-tropic (X4-) HIV-1 entry. Second, Muller et al. reported that the CXCL12-CXCR4 system might determine the metastatic destination of breast cancer cells. Recently, this system has been recognized to be involved in the metastasis of several types of cancers, such as pancreatic cancer, melanoma, prostate cancer, kidney cancer, neuroblastoma, non-Hodgkin's lymphoma, lung cancer, ovarian cancer, multiple myeloma and malignant brain tumor, as well as in the progression of chronic lymphocytic leukemia B-cells and pre-B acute lymphoblastic leukemia cells. Third, Nanki et al. indicated that the interaction between CXCL12 and CXCR4 plays a critical role in T cell accumulation in the RA synovium. Thus, CXCR4 is thought to be an important therapeutic target to overcome the above diseases. Fourteen-mer peptides, T140 and its analogs, were previously found to be specific CXCR4 antagonists that were characterized as HIV entry inhibitors, anti-cancer-metastatic agents, anti-chronic lymphocytic/acute lymphoblastic leukemia agents and anti-RA agents. Based on our knowledge of pharmacophores of T140, CXCR4 antagonists, such as FC131, were found by the efficient utilization of two orthogonal cyclic pentapeptide libraries consisting of conformation-based and sequence-based libraries. We have developed low molecular weight CXCR4 antagonists including FC131 analogs, in which structural tuning of the cyclic peptide ring and chemical modifications were performed for an increase in potency and a reduction of the peptide charcter.

Report

(3 results)
  • 2004 Annual Research Report   Final Research Report Summary
  • 2003 Annual Research Report
  • Research Products

    (19 results)

All 2005 2004 2003 Other

All Journal Article (13 results) Publications (6 results)

  • [Journal Article] Stereoselective Synthesis of [L-Arg, L/D-3-(2-naphthyl)alanine]-Type (E)-Alkene Dipeptide Isosteres and its Application to the Synthesis and Biological Evaluation of Pseudopeptide Analogs of the CXCR4 Antagonist FC131.2005

    • Author(s)
      H.Tamamura, N.Fujii, et al.
    • Journal Title

      J.Med.Chem. 48

      Pages: 380-391

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Stereoselective Synthesis of [L-Arg, L/D-3-(2-naphthyl)alanine]-Type (E)-Alkene Dipeptide Isosteres and its Application to the Synthesis and Biological Evaluation of Pseudopeptide Analogs of the CXCR4 Antagonist FC 131.2005

    • Author(s)
      H.Tamamura, N.Fujii, et al.
    • Journal Title

      J.Med.Chem. 48

      Pages: 380-391

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Topochemical Exploration of Potent Compounds Using Retro-Enantiomer Libraries of Cyclic Pentapeptides.2004

    • Author(s)
      H.Tamamura, N.Fujii, et al.
    • Journal Title

      Org.Biomol.Chem. 2

      Pages: 1255-1257

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Annual Research Report 2004 Final Research Report Summary
  • [Journal Article] Two Orthogonal Approaches to Overcome Multi-Drug Resistant HIV-1s : Development of Protease Inhibitors and Entry Inhibitors Based on CXCR4 Antagonists.2004

    • Author(s)
      H.Tamamura, N.Fujii
    • Journal Title

      Curr.Drug Targets-Infectious Disorders 4・2

      Pages: 103-110

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Annual Research Report 2004 Final Research Report Summary
  • [Journal Article] Two Orthogonal Approaches to Overcome Multi-Drug Resistant HIV-1s : Development of Protease Inhibitors and Entry Inhibitors Based on CXCR4 Antagonists.2004

    • Author(s)
      H.Tamamura, N.Fujii
    • Journal Title

      Curr.Drug Targets-Infectious Disorders 4(2)

      Pages: 103-110

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Stromal Cell-Derived Factor 1-Mediated CXCR4 Signaling in Rat and Human Cortical Neural Progenitor Cells.2004

    • Author(s)
      H.Peng, H.Tamamura, N.Fujii, et al.
    • Journal Title

      J.Neurosci. 76

      Pages: 35-50

    • Related Report
      2004 Annual Research Report
  • [Journal Article] A Single Treatment with Microcapsules Containing a CXCR4 Antagonist Suppresses Pulmonary Metastasis of Murine Melanoma.2004

    • Author(s)
      M.Takenaga, H.Tamamura, N.Fujii, et al.
    • Journal Title

      Biochem.Biophys.Res.Commun. 320・1

      Pages: 226-232

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Identification of a CXCR4 Antagonist, a T140 Analog, as an Anti-rheumatoid Arthritis Agent.2004

    • Author(s)
      H.Tamamura, N.Fujii, et al.
    • Journal Title

      FEBS Lett. 569・1

      Pages: 99-104

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Germinal Center Dark and Light Zone Organization Is Mediated by CXCR4 and CXCR5.2004

    • Author(s)
      C.D.C.Allen, H.Tamamura, N.Fujii, J.G.Cyster, et al.
    • Journal Title

      Nat.Immunol. 5

      Pages: 943-952

    • Related Report
      2004 Annual Research Report
  • [Journal Article] The Therapeutic Potential of CXCR4 Antagonists in the Treatment of HIV.2003

    • Author(s)
      N.Fujii, H.Nakashima, H.Tamamura
    • Journal Title

      Expert Opin.Investig.Drugs 12(2)

      Pages: 185-195

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Reduction of Peptide Character of HIV Protease Inhibitors that Exhibit Nanomolar Potency against Multi-drug Resistant HIV-1 Strains.2003

    • Author(s)
      H.Tamamura, et al.
    • Journal Title

      J.Med.Chem. 46(9)

      Pages: 1764-1768

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Molecular-Size Reduction of a Potent CXCR4-Chemokine Antagonist Using Orthogonal Combination of Conformation- and Sequence-Based Libraries.2003

    • Author(s)
      N.Fujii, H.Tamamura, et al.
    • Journal Title

      Angew.Chem.Int.Ed. 42(28)

      Pages: 3251-3253

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Journal Article] Reduction of Peptide Character of HIV Protease Inhibitors that Exhibit Nanomolar Potency against Multi-drug Resistant HIV-1 Strains.2003

    • Author(s)
      H.Tamamura, et al.
    • Journal Title

      J.Med.Chem. 46

      Pages: 1764-1768

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2004 Final Research Report Summary
  • [Publications] N.Fujii, H.Nakashima, H.Tamamura: "The Therapeutic Potential of CXCR4 Antagonists in the Treatment of HIV"Expert Opin.Investig.Drugs. 12(2). 185-195 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] H.Tamamura, et al.: "Reduction of Peptide Character of HIV Protease Inhibitors that Exhibit Nanomolar Potency against Multi-drug Resistant HIV-1 Strains"J.Med.Chem.. 46(9). 1764-1768 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] N.Fujii, H.Tamamura, et al.: "Molecular-Size Reduction of a Potent CXCR4-Chemokine Antagonist Using Orthogonal Combination of Conformation-and Sequence-Based Libraries"Angew.Chem.Int.Ed.. 42(28). 3251-3253 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] H.Tamamura, et al.: "T140 Analogs as CXCR4 Antagonists Identified as Anti-metastatic Agents in the Treatment of Breast Cancer"FEBS Lett.. 550. 79-83 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] T.Mori, H.Tamamura, et al.: "CXCR4 Antagonist Inhibits Stromal Cell-derived Factor 1-induced Migration and Invasion of Human Pancreatic Cancer"Mol.Cancer Ther.. 3. 29-37 (2004)

    • Related Report
      2003 Annual Research Report
  • [Publications] H.Tamamura, et al.: "Conformationally Constrained Analogues of Diacylglycerol.20.The Search for an Elusive Binding Site on Protein Kinase C(PK-C)through Relocation of the Carbonyl Pharmacophore along the sn-1 Side Chain of DAG-lactones"J.Med.Chem.. 47. 644-655 (2004)

    • Related Report
      2003 Annual Research Report

URL: 

Published: 2003-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi